- Home
- GNS vs BIVI Comparison
GNS vs BIVI Comparison
Compare GNS & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNS
- BIVI
- Stock Information
- Founded
- GNS 2002
- BIVI 2013
- Country
- GNS Singapore
- BIVI United States
- Employees
- GNS N/A
- BIVI N/A
- Industry
- GNS Other Consumer Services
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- GNS Real Estate
- BIVI Health Care
- Exchange
- GNS Nasdaq
- BIVI Nasdaq
- Market Cap
- GNS 23.4M
- BIVI 18.8M
- IPO Year
- GNS 2022
- BIVI N/A
- Fundamental
- Price
- GNS $0.25
- BIVI $0.95
- Analyst Decision
- GNS
- BIVI Strong Buy
- Analyst Count
- GNS 0
- BIVI 1
- Target Price
- GNS N/A
- BIVI $30.00
- AVG Volume (30 Days)
- GNS 1.6M
- BIVI 230.4K
- Earning Date
- GNS 05-14-2025
- BIVI 05-13-2025
- Dividend Yield
- GNS N/A
- BIVI N/A
- EPS Growth
- GNS N/A
- BIVI N/A
- EPS
- GNS N/A
- BIVI N/A
- Revenue
- GNS $16,147,348.00
- BIVI N/A
- Revenue This Year
- GNS N/A
- BIVI N/A
- Revenue Next Year
- GNS $47.43
- BIVI N/A
- P/E Ratio
- GNS N/A
- BIVI N/A
- Revenue Growth
- GNS N/A
- BIVI N/A
- 52 Week Low
- GNS $0.21
- BIVI $0.80
- 52 Week High
- GNS $5.69
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- GNS 38.79
- BIVI 37.09
- Support Level
- GNS $0.21
- BIVI $0.99
- Resistance Level
- GNS $0.33
- BIVI $1.10
- Average True Range (ATR)
- GNS 0.04
- BIVI 0.10
- MACD
- GNS -0.00
- BIVI 0.01
- Stochastic Oscillator
- GNS 30.36
- BIVI 34.07
About GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education - entrepreneur education, management consultancy, and business development tools; and Campus - resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.